• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Intersect ENT posts mixed-bag Q1 earnings

May 6, 2019 By Fink Densford

Intersect ENT updated

Intersect ENT (NSDQ:XENT) today posted first quarter earnings that topped sales expectations but missed loss-per-share consensus on Wall Street.

The Menlo Park, Calif.-based company posted losses of $10.8 million, or 35¢ per share, on sales of $26.7 million for the three months ended March 31, seeing losses grow 76.1% while sales grew 7.9% compared with the same period during the previous year.

Losses per share were 5¢ behind the -30¢ Wall Street consensus, where analysts expected to see sales of $26.3 million, which the company topped.

“We continue to work closely with physicians on the introduction of SINUVA and are pleased with the positive feedback regarding patient outcomes. While we have made strides in facilitating product access and sales force balance, we are implementing further measures to continue to improve these areas. We are encouraged by the preliminary decision by CMS to assign a J code, and remain excited about the opportunity for Sinuva,” prez & CEO Lisa Earnhardt said in a press release.

The company released reduced sales guidance for the full year 2019, now expecting to post sales of between $113 million and $117 million, down from earlier guidance of between $123 million to $127 million.

Shares in Intersect ENT fell 1.5% today, closing at $33.15.

Last month, shares in Intersect ENT got a boost on news that the Centers for Medicare and Medicaid Services had assigned the company’s Sinuva corticosteroid-eluting sinus implant a preliminary J-code.

Filed Under: Business/Financial News, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Intersect ENT Inc.

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS